Genpact Limited registered 180,845,599 shares of common stock for issuance in connection with a proposed domestication from Bermuda to Delaware. Separately, 167,227,006 common shares were issued and outstanding and entitled to vote as of September 30, 2026. Shareholders will vote at a special meeting on November 10, 2026.
If approved, the Board would have sole discretion to effect the move until the 2028 Annual General Meeting, subject to final Board approval. Completion is expected on or around March 1, 2027, but the Board may delay or abandon it. At effectiveness, each outstanding Bermuda common share would convert into an equivalent Delaware common share, preserving proportional ownership; equity awards would also convert into equivalent awards, generally on the same terms.
Genpact says its business, assets, liabilities, ownership and fiscal year would remain unchanged, with accounting treated as a continuation of the existing reporting entity. Delaware law and the new charter and bylaws would change some shareholder rights, including anti-takeover and exclusive-forum provisions. Genpact expects cost savings but says the effective tax rate could change and expected benefits may not be realized.
Genpact LTD (symbol: G) is the issuer of record for a Form S-4/A filing submitted to the SEC.
Genpact Limited (G) filed an amendment detailing the separation terms for former Chief Financial Officer Michael Weiner, who stepped down on September 8, 2026 and will serve in a transitional role through March 31, 2027. Under a September 15, 2026 Separation Agreement, he will receive continued salary and benefits through the Separation Date, a severance equal to 12 months of base salary, cash in lieu of 18 months of health coverage, a prorated 2027 target bonus, partial accelerated vesting of certain equity awards based on an additional 12 months of deemed service and performance outcomes, and a six-month post-separation option exercise window. These payments are conditioned on his signing and re-signing a general release and complying with one-year non-compete, non-solicitation, confidentiality, and non-disparagement covenants.
Genpact Limited (G) has filed Amendment No. 1 to a Form S-4 to register 180,845,599 shares of common stock to be issued in a one-for-one share conversion in connection with a proposed domestication from Bermuda to Delaware, expected to be completed on or around March 1, 2027, subject to shareholder and board approval.
Each existing Bermuda common share will automatically convert into an equivalent Delaware common share with the same par value and NYSE ticker “G,” with no change to the company’s business, assets, liabilities, executive team, or board. The domestication is presented as a corporate reorganization aimed at simplifying Genpact’s geographic structure, aligning with its predominantly U.S.-based leadership, achieving internal cost efficiencies, and potentially broadening institutional ownership and liquidity under a more familiar Delaware legal framework.
Shareholders will vote at a special meeting on a Domestication Proposal granting the board discretion to effect the move any time until the 2028 annual meeting, and on an Adjournment Proposal that would allow the meeting to be delayed to solicit additional proxies. The filing highlights changes in shareholder rights under Delaware law, new anti-takeover and exclusive forum provisions, the absence of appraisal rights, expected transaction costs, and complex U.S. federal income tax considerations, including treatment as a potential F reorganization and PFIC-related rules.
Genpact LTD (G) reports that President and CEO Balkrishan Kalra sold 10,000 Common Shares on September 14, 2026 in a sale in open market or private transaction at a weighted average price of $36.79, with individual sale prices ranging from $36.790 to $36.795. Following this transaction, he directly holds 501,114 Common Shares, and no Rule 10b5-1 trading plan is reported.
Genpact Limited (G) received a notice that insider Balkrishan Kalra intends to sell 10,000 shares of common stock under Rule 144 through broker Morgan Stanley Smith Barney LLC. The planned sale has an approximate aggregate value of $367,904 and is listed for execution on September 14, 2026 on the NYSE.
Genpact LTD (G) reported that its Chief Financial Officer, Sumita Pandit, received a grant of 76,713 Common Shares in the form of unvested restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan on September 9, 2026. Each RSU converts into one common share upon vesting, and Pandit now holds 76,713 common shares directly. One-third of the RSUs will vest on each of September 9, 2027, September 9, 2028, and September 9, 2029, subject to her continued service. No Rule 10b5-1 trading plan is reported.
Genpact LTD (G) filed an initial ownership report for Sumita Pandit, who serves as Chief Financial Officer. The filing is a Form 3 and reports no transactions and no holdings of Genpact securities at the time of filing. The remarks reference an attached Power of Attorney authorizing the filing.
Genpact Limited (G) appointed Sumita Pandit as Senior Vice President and Chief Financial Officer effective September 9, 2026, replacing Michael Weiner, who will stay in a transitional role through March 31, 2027 and whose departure is stated as not related to accounting or internal control disagreements.
Pandit’s employment agreement provides a $750,000 annual base salary, an annual target bonus equal to 120% of base salary, and a one-time bonus totaling $3,000,000 payable in December 2026 and December 2027, subject to performance. She will receive initial equity awards of PSUs and RSUs each valued at $2,675,000, with vesting based on performance and service. The agreement also outlines severance, accelerated vesting and health benefit payments upon certain terminations, including enhanced treatment following a change of control, subject to a release of claims and restrictive covenants.